Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M134,235Revenue $M44,175Net Margin (%)20.5Z-Score2.5
Enterprise Value $M155,464EPS $3.7Operating Margin %26.5F-Score6
P/E(ttm))15.0Cash Flow Per Share $4.7Pre-tax Margin (%)25.1Higher ROA y-yY
Price/Book11.410-y EBITDA Growth Rate %3.1Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.15-y EBITDA Growth Rate %2.4Current Ratio1.1Lower Leverage y-yN
Price/Cash Flow9.3y-y EBITDA Growth Rate %1.1ROA % (ttm)12.9Higher Current Ratio y-yY
Dividend Yield %4.5Insider Buy (3m)0ROE % (ttm)77.7Less Shares Outstanding y-yY
Payout Ratio %70.0Shares Outstanding M2,451ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 54.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 55.37%Add 1702.13%423,500
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 55.37%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 55.37%New holding, 83452 sh.83,452
GSKVanguard Health Care Fund 2013-12-31 Reduce-0.14%$49.31 - $53.68
($51.87)
$ 55.37%Reduce -55.18%644,881
GSKWarren Buffett 2013-12-31 Sold Out -0.02%$49.31 - $53.68
($51.87)
$ 55.37%Sold Out0
GSKWarren Buffett 2013-09-30 Reduce-0.06%$50.27 - $52.96
($51.54)
$ 55.37%Reduce -76.57%345,819
GSKJoel Greenblatt 2013-06-30 Sold Out -0.16%$46.79 - $53.59
($50.77)
$ 55.39%Sold Out0
GSKVanguard Health Care Fund 2013-06-30 Reduce-0.1%$46.79 - $53.59
($50.77)
$ 55.39%Reduce -26.11%1,611,181
GSKJean-Marie Eveillard 2013-06-30 Reduce-0.05%$46.79 - $53.59
($50.77)
$ 55.39%Reduce -100%1
GSKJohn Hussman 2013-03-31 Reduce-0.57%$43.47 - $46.91
($44.97)
$ 55.323%Reduce -95.51%23,500
GSKVanguard Health Care Fund 2013-03-31 Reduce-0.07%$43.47 - $46.91
($44.97)
$ 55.323%Reduce -20.49%2,180,381
GSKJohn Hussman 2012-12-31 Add0.58%$41.9 - $47.45
($44.3)
$ 55.325%Add 2584.62%523,500
GSKDodge & Cox 2012-12-31 Add0.18%$41.9 - $47.45
($44.3)
$ 55.325%Add 5.08%63,302,825
GSKTweedy Browne 2012-12-31 Add0.03%$41.9 - $47.45
($44.3)
$ 55.325%Add 20.16%151,264
GSKJoel Greenblatt 2012-12-31 Reduce-0.09%$41.9 - $47.45
($44.3)
$ 55.325%Reduce -32.53%60,720
GSKJoel Greenblatt 2012-09-30 Buy 0.28%$44.25 - $47.23
($46.06)
$ 55.320%New holding, 89990 sh.89,990
GSKJean-Marie Eveillard 2012-03-31 Buy 0.06%$43.73 - $46.35
($42.21)
$ 55.331%New holding, 322701 sh.322,701
GSKCharles Brandes 2011-12-31 Reduce-0.3%$40.53 - $45.74
($44)
$ 55.326%Reduce -20.33%3,035,713
GSKJohn Hussman 2011-09-30 Add$38.84 - $44.91
($42.39)
$ 55.330%Add 50%16,500
GSKDavid Dreman 2011-09-30 Sold Out -0.0722%$38.84 - $44.91
($42.39)
$ 55.330%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK Joel Greenblatt 2013-12-3183,45200.11New Buy
GSK John Hussman 2013-12-31423,5000.021.6+1702.13%
GSK Charles Brandes 2013-12-312,145,4610.091.4+13.11%
GSK Jean-Marie Eveillard 2013-12-31100
GSK Tweedy Browne 2013-12-31150,1840.010.19-0.56%
GSK PRIMECAP Management 2013-12-319,998,8770.410.64-0.79%
GSK Dodge & Cox 2013-12-3160,479,6502.473.4-1.32%
GSK Vanguard Health Care Fund 2013-12-31644,8810.030.11-55.18%
GSK Warren Buffett 2013-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12342.67view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14279.43view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12342.67view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      GlaxoSmithKline Finally Received Approval from FDA for Its Diabetes Drug Tanzeum (Albiglutide) Apr 19 2014 
      Why Buy-and-Hold-Forever Buffett’s Company Just Sold Two Stocks Feb 27 2014 
      10 British Stocks to Consider Feb 20 2014 
      Novartis' 'Cliffy' Business Feb 07 2014 
      Tweedy Browne Global Value Fund New Buy and Adds Jan 23 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 
      Sanofi Continues to Struggle on Its Path to Recovery Nov 23 2013 
      GuruFocus Weekly Dividend Growers Pt. I Oct 28 2013 
      Top Yields in Berkshire Hathaway’s Portfolio Oct 08 2013 

      More From Our Partners
      Glaxo Looking into Misconduct Charges - Analyst Blog Apr 17 2014 - ZACKS

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Hide